SKL37321 / WARF Therap, University of Wisconsin - Madison, SK Bio - LARVOL DELTA

Preclinical evaluation of SKL37322/SKL37321, a matched ⁶⁸Ga/¹⁷⁷Lu-labeled CAIX-targeted theranostic pair for clear cell renal cell carcinoma (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • CA9

SK biopharmaceuticals said it has signed a license-in agreement with the Wisconsin Alumni Research Foundation (WARF) for global development and commercialization rights to WT-7695, an experimental radiopharmaceutical therapy (RPT) candidate, as the Korean company deepens its push into next-generation cancer treatments. (Korea Biomedical Review)

Licensing / partnership • Clear Cell Renal Cell Carcinoma

SHINE Technologies Collaborates with University of Wisconsin-Madison and WARF Therapeutics to Create Promising New Treatments for Kidney and Prostate Cancers (PRNewswire) - "SHINE Technologies...and WARF Therapeutics...announced promising pre-clinical research results from collaborative efforts with Advanced Radiotheranostics Lab at the University of Wisconsin-Madison....The initial pre-clinical results of 177Lu-WT-7695 show unprecedently high tumor uptake at 24h and significant tumor retention at seven days. Consequently, treatment studies lead to significant tumor regression and 100% survival in a mouse model of kidney cancer. WT-7695 is a best-in-class CA9 radiopharmaceutical and is moving into IND-enabling studies in early 2025....The study showed that ART-101 demonstrated superior tumor growth inhibition compared to existing radiopharmaceuticals targeting the prostate specific membrane antigen....The group plans to have WT-7695 and ART-101 move on to human trials within the next year."

New trial • Preclinical • Kidney Cancer • Prostate Cancer • Renal Cell Carcinoma